NURECA
|
|
BOM : 543264     NSE : NURECA     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : NA |
Dec 04,2023 |
Price(EOD): ₹ 359.40
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Trading |
MCap: ₹ 359.40 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
NURECA | NA | 0.1% | -31.7% |
ADANI ENTERPRISES | 4.4% | 14.2% | -39.1% |
REDINGTON (INDIA) | 1.5% | 12.1% | -10.4% |
MMTC | 1.7% | -4.8% | 24.5% |
OPTIEMUS INFRACOM | 10.8% | 14.8% | 34.5% |
MSTC | 2% | -2.2% | 26.6% |
SIRCA PAINTS INDIA | 6.1% | 7.8% | NA |
POLO QUEEN INDUSTRIAL & FINTECH | -2.6% | -13.8% | -14.7% |
NOVARTIS INDIA | 2.8% | 9.5% | 5% |
FUNDAMENTAL ANALYSIS OF NURECA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF NURECA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
375.17
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 0.96 Cr
[Latest Qtr - Sep2023 - Consolidated Results ] 1.84
P/B Calculated based on Book Value of Rs 194.88 Cr
[Latest Year - Mar2023 - Consolidated Results ] 3.54
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 101.60 Cr
[Latest Qtr - Sep2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
69% 106% -13% |
SHARE PRICE MOMENTUM OF NURECA
NURECA vs SENSEX
DEBT OF NURECA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.01 0.01 0.69 0.24 |
0.01 0.01 0.7 0.24 |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF NURECA
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF NURECA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
47.68% 147.71% 521.1% 509.34% |
-14.76% 128.22% 204.63% 200.07% |
QtrlyTrend |
6 | |
Latest Qtr: Sep2023 | ||
Quarterly Result Analysis → |
NURECA related INDICES
You may also like the below Video Courses
FAQ about NURECA
Is NURECA good for long term investment?
As on Dec 04,2023, the Fundamentals of NURECA look Strong and hence it may be good for long term investment! See Financial Performance of NURECA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is NURECA UnderValued or OverValued?
As on Dec 04,2023, NURECA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of NURECA ?
As on Dec 04,2023, the Intrinsic Value of NURECA is Rs. 212.45 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 212.45
Fair Value [Median EV / Sales Model] : Rs. 174.20
Fair Value [Median Price / Sales Model] : Rs. 414.01
Estimated Median Fair Value of NURECA : Rs. 212.45
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is NURECA trading at a Premium or Discount?
As on Dec 04,2023, NURECA is trading at a Premium of 69% based on the estimates of Median Intrinsic Value!ADANI ENTERPRISES LTD vs REDINGTON LTD vs MMTC LTD
OPTIEMUS INFRACOM LTD vs MSTC LTD vs SIRCA PAINTS INDIA LTD
